Ginkgo Bioworks: The Bill Gates-Backed Synthetic Biology Unicorn, From SPAC Bubble to Extreme Survival

Origin

In 2008, MIT computer science professor Tom Knight introduced the concept of 'standardized biological design,' arguing that biological programming should be as modular as writing computer programs. He co-founded Ginkgo Bioworks alongside four students—Jason Kelly, Reshma Shetty, Barry Canton, and Austin Che—in his synthetic biology laboratory at MIT. Professor Knight, a former core member of the MIT Computer Systems Laboratory who participated in early ARPANET design, pivoted to biology at age 50 and laid the foundational concept of synthetic biology that cells can be 'programmed' like computer chips. The five founders used an experiment introducing rose scent genes into yeast as their first commercial validation, enabling yeast to autonomously produce rose fragrance to replace expensive natural extraction, thereby validating the prototype of the 'microbial industrial foundry' model. Ginkgo positioned itself as 'The Organism Company,' helping agricultural, food, and consumer goods companies design microbial strains and saving clients from repeating early-stage R&D costs.

Milestones

Turning Points

• In 2008, MIT professor Tom Knight led four graduate students to found Ginkgo, using the rose scent yeast project to validate the microbial foundry model's transition from academia to commerce.
• In 2016, the world's first automated biofoundry, Biofoundry, was built in Boston, upgrading the company from a manual laboratory to a robotic parallel gene-editing platform and propelling it to unicorn valuation.
• In September 2021, the company went public via SPAC at a $15 billion valuation in the largest SPAC deal to date, raising $2.5 billion, though an 85x P/S valuation signaled a potential bubble.
• In 2023, as Biosecurity pandemic tailwinds faded, the Cell Engineering platform business failed to fill the revenue gap, sending the stock price below $1 and exposing slow growth in the core business model.
• In 2025, the complete spinoff of the Concentric molecular diagnostics subsidiary from core operations, retrenching to the Cell Engineering core business and setting a late-2026 EBITDA breakeven target, represented a final self-rescue attempt.

Failures & Pitfalls

• Following the end of federal COVID testing contracts in 2023, the Biosecurity division's quarterly revenue plummeted from a peak of $100 million to a few million dollars, causing the stock price to drop from over $15 to below $1 and facing delisting warnings.
• In 2024, the company was forced to cut 35% of its workforce (about 400 employees), shrinking its headcount by over a third from 1,218, as the CEO publicly acknowledged a life-or-death restructuring forced by dual pressures of falling revenue and widening losses.
• In October 2024, a forced 1-for-40 reverse stock split barely kept the company clear of delisting before its share price resumed falling, leaving capital market trust unrestored and refinancing difficult.
• In Q2 2026, revenue of $20.2 million fell far short of the $29.9 million market consensus, missing the EBITDA breakeven target and keeping the company under severe pressure in a volatile survival mode that risks premature capital exhaustion.

Core Data

• 借壳上市估值：$15 billion (September 2021) (Company disclosed figure, as of 2026, unverified by independent audit)
• 2019年私募估值：$4.2 billion (Company disclosed figure, as of 2026, unverified by independent audit)
• 2022年全年营收：Approx. $490 million (Company disclosed figure, as of 2026, unverified by independent audit)
• 2025年全年营收指引：$167-187 million (Company disclosed figure, as of 2026, unverified by independent audit)
• 2025年细胞工程业务营收：$117-137 million (Company disclosed figure, as of 2026, unverified by independent audit)
• 2025年生物安全业务营收：$37 million (Full year) (Company disclosed figure, as of 2026, unverified by independent audit)
• 2026年二季度营收：$20.2 million (Company disclosed figure, as of 2026, unverified by independent audit)
• 2026年二季度净亏损：$57.3 million (Company disclosed figure, as of 2026, unverified by independent audit)
• 2024年裁员人数：Approx. 400 people (35% of workforce) (Company disclosed figure, as of 2026, unverified by independent audit)
• 上市后裁员前员工数：1,218 employees (Company disclosed figure, as of 2026, unverified by independent audit)

Competitors / Peers

Ginkgo Bioworks' main competitors in the synthetic biology platform space include Zymergen and Amyris, all of which experienced valuation collapses following SPAC or IPO listings. Zymergen was Ginkgo's most direct competitor in the biofoundry platform business, similarly pursuing a robotic automated lab model; following its 2021 public listing, core product failure led to a valuation collapse, and it was ultimately acquired by Ginkgo for partial asset absorption in 2022. Amyris focused on synthetic biology ingredients for personal care and consumer goods, filing for bankruptcy protection in 2023 due to debt issues, with its core strain assets sold off in pieces. In the gene-editing tools sector, Synthego and Twist Bioscience entered with more vertical CRISPR reagents and DNA synthesis services, forming a differentiated competitive dynamic against Ginkgo's platform outsourcing model. In agriculture, Ginkgo's joint venture with Bayer leverages microbial design to develop agricultural biologicals, competing against the internal R&D of traditional agrochemical giants like Corteva and Syngenta. Overall, the commercialization validation cycle for synthetic biology platform companies is extremely long, and several peers experienced similar dilemmas of post-SPAC valuation crashes and forced restructuring between 2021 and 2023. Whether Ginkgo can achieve EBITDA breakeven by the end of 2026 serves as a key industry validation of the viability of the synthetic biology platform model.